---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015206"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:37:00.751550+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vanda Q1 2023 revenue $62.5M (+4% YoY); net income $3.3M vs loss

## Summary
- Net product sales: HETLIOZ $39.6M (+7% YoY), Fanapt $22.9M (-1% YoY).
- Diluted EPS $0.06 vs ($0.11) in prior year; cash $501.5M (+15% YoY).
- Expects sNDA for Fanapt in bipolar I disorder and NDA for tradipitant in gastroparesis in Q2 2023.
- At-risk generic HETLIOZ launch in U.S. likely to cause significant future sales decline; no 2023 guidance provided.
- Awaiting Federal Circuit ruling on HETLIOZ patent appeal; won FOIA lawsuit against FDA.

## SEC filing metadata
- accession: 0001628280-23-015206
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/0001628280-23-015206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/vnda-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015206
- JSON: https://secwatch.observer/filing/0001628280-23-015206.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015206.txt

## Key facts
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $62.5 million, net income $3.3 million, EPS diluted net income per share was $0.06.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $62.5 million
  - Net income: $3.3 million
  - EPS: diluted net income per share was $0.06
  - Result: reported results
  source text: set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results • Q1 2023 total revenues were $62.5 million • Vanda provides update on three upcoming regulatory submissions WASHINGTON – May 3, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/0001628280-23-015206-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.